Genentech, Inc.
NEWS
BioNTech, headquartered in Mainz, Germany, and Pfizer, based in New York City, signed a multi-year research-and-development deal to develop mRNA-based flu vaccines.
This morning Genentech announced the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to Xolair to treat exposure to those deadly food allergies.
GlaxoSmithKline Chief Executive Officer Emma Walmsley has made another key appointment to her senior leadership team.
IGM Biosciences, a privately-held biotech company located in Mountain View, California, announced that Daniel S. Chen will be the company’s new chief medical officer. Chen arrives from Genentech/Roche, where he was most recently vice president, Global Head of Cancer Immunotherapy.
BioLineRx, based in Tel Aviv, Israel, and Merck & Co, based in Kenilworth, New Jersey, announced they are expanding their immuno-oncology collaboration.
Genentech and Horizon Pharma were the only two biopharma companies that made People’s 2018 list of “50 Companies That Care,” a list that highlights how a company makes a difference in the lives of its employees, as well as the communities those companies call home.
Nearly four months after acquiring 100 percent control of its consumer health unit, GlaxoSmithKline Chairman Philip Hampton may be pushing for the business to become a standalone entity apart from its pharma and vaccines division, according to The Financial Times.
With flu season fast approaching, Genentech has some good news for people who are at high risk of complications from the illness.
Two well-known pharmaceutical companies made Fortune Magazine’s 2018 top 100 Best Workplaces for Millennials.
JOBS
IN THE PRESS
